$INO
INOVIO PHARMACEUTICALS, INC. Stock $ino

$ino Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000105572621000018 Filed on March 01, 2021

Income Statement

Concept	2020 Q4	2020 Q3	2020 Q2
Revenue	$5.581M	$236.2K	$267.2K
YoY Change	1896.72%	-72.75%	96.93%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.620M	$10.11M	$11.07M
YoY Change	-0.92%	77.99%	89.23%
% of Gross Profit
Research & Development	$26.30M	$26.46M	$22.38M
YoY Change	19.54%	38.24%	-0.49%
% of Gross Profit
Depreciation & Amortization	$860.0K	$850.0K	$930.0K
YoY Change	-23.21%	-26.72%	-21.85%
% of Gross Profit
Operating Expenses	$34.92M	$36.57M	$33.45M
YoY Change	13.74%	47.33%	18.04%
Operating Profit	-$29.34M	-$36.33M	-$33.18M
YoY Change	-3.56%	51.68%	17.66%
Interest Expense	$1.068M	$1.984M	$2.847M
YoY Change	-59.98%	-18.31%	29.7%
% of Operating Profit
Other Income/Expense, Net	$9.350K	-$136.6K	-$152.1K
YoY Change	-96.45%	-196.94%	-219.28%
Pretax Income	-$22.42M	$20.93M	-$128.3M
YoY Change	-41.38%	-188.93%	332.09%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income		0.0%
Net Earnings	-$24.34M	$19.17M	-$128.7M
YoY Change	-35.38%	-183.03%	337.96%
Net Earnings / Revenue	-436.13%	8117.33%	-48169.66%
Basic Earnings Per Share	-$0.14	$0.12	-$0.83
Diluted Earnings Per Share	-$0.14	$0.11	-$0.83
COMMON SHARES
Basic Shares Outstanding	169.4M shares	165.4M shares	155.8M shares
Diluted Shares Outstanding		174.4M shares	155.8M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$411.6M	$337.2M	$371.7M
YoY Change	359.89%	259.49%	250.66%
Cash & Equivalents	$250.7M	$178.7M	$215.4M
Short-Term Investments	$160.9M	$158.5M	$156.2M
Other Short-Term Assets	$40.50M	$31.60M	$6.400M
YoY Change	1457.69%	857.58%	88.24%
Inventory
Prepaid Expenses
Receivables	$18.56M	$7.693M	$3.513M
Other Receivables	$500.0K	$500.0K	$500.0K
Total Short-Term Assets	$471.2M	$377.1M	$382.1M
YoY Change	400.18%	281.6%	245.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.35M	$11.19M	$11.32M
YoY Change	-11.16%	-17.21%	-20.63%
Goodwill	$10.51M	$10.51M	$10.51M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$3.147M	$3.300M	$3.400M
YoY Change	-14.81%	-16.68%	-19.57%
Long-Term Investments	$434.4K	$957.6K	$2.717M
YoY Change		-88.03%	-68.03%
Other Assets	$25.96M	$17.64M	$2.556M
YoY Change	871.45%	545.97%	-10.42%
Total Long-Term Assets	$68.60M	$60.75M	$61.12M
YoY Change	37.89%	15.23%	12.02%
TOTAL ASSETS
Total Short-Term Assets	$471.2M	$377.1M	$382.1M
Total Long-Term Assets	$68.60M	$60.75M	$61.12M
Total Assets	$539.8M	$437.8M	$443.2M
YoY Change	274.97%	188.92%	168.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$21.80M	$24.30M	$17.70M
YoY Change	14.74%	138.24%	26.43%
Accrued Expenses	$12.30M	$8.100M	$9.100M
YoY Change	101.64%	79.96%	96.19%
Deferred Revenue	$46.63K	$77.88K	$14.85K
YoY Change	-49.51%	-26.61%	-87.69%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$41.71M	$41.26M	$37.98M
YoY Change	30.37%	111.1%	57.74%
LONG-TERM LIABILITIES
Long-Term Debt	$18.70M	$53.70M	$79.60M
YoY Change	-75.71%	-23.4%	26.75%
Other Long-Term Liabilities	$57.66K	$39.78K	$66.63K
YoY Change	56.09%	-20.99%	31.26%
Total Long-Term Liabilities	$57.66K	$39.78K	$66.63K
YoY Change	56.09%	-20.99%	31.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$41.71M	$41.26M	$37.98M
Total Long-Term Liabilities	$57.66K	$39.78K	$66.63K
Total Liabilities	$78.63M	$113.8M	$256.8M
YoY Change	-43.25%	-1.39%	136.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$906.2M	-$881.9M	-$901.0M
YoY Change	22.49%	25.6%	32.69%
Common Stock	$186.9K	$167.5K	$158.8K
YoY Change	84.34%	69.14%	61.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$461.1M	$323.9M	$186.3M
YoY Change
Total Liabilities & Shareholders Equity	$539.8M	$437.8M	$443.2M
YoY Change	274.97%	188.92%	168.48%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2020 Q2
OPERATING ACTIVITIES
Net Income	-$24.34M	$19.17M	-$128.7M
YoY Change	-35.38%	-183.03%	337.96%
Depreciation, Depletion And Amortization	$860.0K	$850.0K	$930.0K
YoY Change	-23.21%	-26.72%	-21.85%
Cash From Operating Activities	-$51.22M	-$74.16M	-$27.15M
YoY Change	272.78%	167.44%	13.46%
INVESTING ACTIVITIES
Capital Expenditures	-$960.0K	-$380.0K	-$40.00K
YoY Change	700.0%	192.31%	-50.0%
Acquisitions
YoY Change
Other Investing Activities	-$2.760M	$39.50M	-$42.35M
YoY Change	-126.16%	370.24%	-295.43%
Cash From Investing Activities	-$3.720M	$39.11M	-$42.38M
YoY Change	-135.67%	372.91%	-296.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	126.9M	-1.700M	126.5M
YoY Change	1215.44%	-110.91%	9708.53%
NET CHANGE
Cash From Operating Activities	-51.22M	-74.16M	-27.15M
Cash From Investing Activities	-3.720M	39.11M	-42.38M
Cash From Financing Activities	126.9M	-1.700M	126.5M
Net Change In Cash	72.00M	-36.75M	57.00M
YoY Change	1035.65%	847.16%	-5528.57%
FREE CASH FLOW
Cash From Operating Activities	-$51.22M	-$74.16M	-$27.15M
Capital Expenditures	-$960.0K	-$380.0K	-$40.00K
Free Cash Flow	-$50.26M	-$73.78M	-$27.11M
YoY Change	269.02%	167.32%	13.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001055726
CY2017	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201601Member
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	660 W. Germantown Pike
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19462
CY2020	dei	City Area Code CityAreaCode	267
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-14888
CY2020	dei	Entity Registrant Name EntityRegistrantName	INOVIO PHARMACEUTICALS, INC.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0969592
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 110
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Plymouth Meeting
CY2020	dei	Local Phone Number LocalPhoneNumber	440-4200
CY2020	dei	Security12b Title Security12bTitle	COMMON STOCK, $0.001 PAR VALUE
CY2020	dei	Trading Symbol TradingSymbol	INO
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	4200000000	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	207632584	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	250728118	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22196097	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	160914935	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	67338017	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18559967	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	700073	USD
CY2020Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	503782	USD
CY2019Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	1332044	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	40357456	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1584598	USD
CY2020Q4	ino	Prepaid Expenses And Other Current Assets From Affiliated Entity PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	106432	USD
CY2019Q4	ino	Prepaid Expenses And Other Current Assets From Affiliated Entity PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	1050140	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	471170690	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	94200969	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11348144	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12773017	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	4460366	USD
CY2019Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	6315356	USD
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	434387	USD
CY2019Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3146770	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3693851	USD
CY2020Q4	us-gaap	Goodwill Goodwill	10513371	USD
CY2019Q4	us-gaap	Goodwill Goodwill	10513371	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12741296	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13783009	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	25957448	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2672024	USD
CY2020Q4	us-gaap	Assets Assets	539772472	USD
CY2019Q4	us-gaap	Assets Assets	143951597	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	21203808	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	18237258	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	642969	USD
CY2019Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	729729	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2074842	USD
CY2020Q4	ino	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	9950345	USD
CY2019Q4	ino	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	4049727	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	46628	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	92353	USD
CY2020Q4	ino	Deferred Revenue From Affiliated Entity Current DeferredRevenueFromAffiliatedEntityCurrent	0	USD
CY2019Q4	ino	Deferred Revenue From Affiliated Entity Current DeferredRevenueFromAffiliatedEntityCurrent	31775	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2329394	USD
CY2020Q4	ino	Deferred Grant Funding Current DeferredGrantFundingCurrent	7474310	USD
CY2019Q4	ino	Deferred Grant Funding Current DeferredGrantFundingCurrent	6065212	USD
CY2020Q4	ino	Deferred Grant Funding From Affiliate Current DeferredGrantFundingFromAffiliateCurrent	58500	USD
CY2019Q4	ino	Deferred Grant Funding From Affiliate Current DeferredGrantFundingFromAffiliateCurrent	708425	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41705954	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31989321	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	79214	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	101567	USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2019Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	8819023	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18063515	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20409922	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	32046	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	32046	USD
CY2020Q4	ino	Deferred Grant Funding From Affiliate Noncurrent DeferredGrantFundingFromAffiliateNoncurrent	37500	USD
CY2019Q4	ino	Deferred Grant Funding From Affiliate Noncurrent DeferredGrantFundingFromAffiliateNoncurrent	135000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	57663	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	36943	USD
CY2020Q4	us-gaap	Liabilities Liabilities	78631714	USD
CY2019Q4	us-gaap	Liabilities Liabilities	138546739	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	9	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	9	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	23	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	23	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	186851493	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	186851493	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	101361034	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	101361034	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	186851	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	101361	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1367406869	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	742646785	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-906196812	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-739785655	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-256150	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	472608	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	461140758	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	3435099	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	0	USD
CY2019Q4	us-gaap	Minority Interest MinorityInterest	1969759	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	461140758	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5404858	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	539772472	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	143951597	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7411220	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4111930	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30481897	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	94245436	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	88017319	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	95257876	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37247828	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27203156	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29315159	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	131493264	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	115220475	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	124573035	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-124082044	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-111108545	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-94091138	USD
CY2020	us-gaap	Interest Income Operating InterestIncomeOperating	3311846	USD
CY2019	us-gaap	Interest Income Operating InterestIncomeOperating	2605981	USD
CY2018	us-gaap	Interest Income Operating InterestIncomeOperating	2264747	USD
CY2020	us-gaap	Interest Expense InterestExpense	8702450	USD
CY2019	us-gaap	Interest Expense InterestExpense	7948539	USD
CY2018	us-gaap	Interest Expense InterestExpense	0	USD
CY2020	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	0	USD
CY2019	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	0	USD
CY2018	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	360795	USD
CY2020	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-75670977	USD
CY2019	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-1763652	USD
CY2018	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	0	USD
CY2020	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	36556658	USD
CY2019	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-3090557	USD
CY2018	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-1988567	USD
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	1695497	USD
CY2019	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	USD
CY2018	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-704896	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	496200	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1343856	USD
CY2020	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	4121075	USD
CY2019	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2018	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-162890304	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-120809112	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-94798019	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-257335	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2169811	USD
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4584610	USD
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2018	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-167474914	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-120551777	USD
CY2018	us-gaap	Profit Loss ProfitLoss	-96967830	USD
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1063757	USD
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1192558	USD
CY2018	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-166411157	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-119359219	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-96967830	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.07
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.21
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.05
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	155126857	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	98717999	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92539997	shares
CY2020	us-gaap	Profit Loss ProfitLoss	-167474914	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-120551777	USD
CY2018	us-gaap	Profit Loss ProfitLoss	-96967830	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	27205	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-755963	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1001475	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-180496	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-168203672	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-119550302	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-97148326	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1063757	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1192558	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-167139915	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-118357744	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-97148326	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	142488809	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	29227776	USD
CY2018	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1809526	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10654622	USD
CY2018	us-gaap	Profit Loss ProfitLoss	-96967830	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-180496	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	87032407	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9089009	USD
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-780405	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	15752698	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10901320	USD
CY2019	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	2960131	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-120551777	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1001475	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5404858	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	454486400	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8241624	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15647523	USD
CY2020	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	2379969	USD
CY2020	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	3181640	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-167474914	USD
CY2020	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	0	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-755963	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	27205	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	461140758	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-167474914	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-120551777	USD
CY2018	us-gaap	Profit Loss ProfitLoss	-96967830	USD
CY2020	us-gaap	Depreciation Depreciation	3038996	USD
CY2019	ino	Non Cash Interest Expense NonCashInterestExpense	5230954	USD
CY2019	us-gaap	Depreciation Depreciation	3598388	USD
CY2018	us-gaap	Depreciation Depreciation	3747183	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	547081	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1066294	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1249584	USD
CY2020	ino	Amortization Of Operating Lease Right Of Use Assets AmortizationOfOperatingLeaseRightOfUseAssets	1041713	USD
CY2019	ino	Amortization Of Operating Lease Right Of Use Assets AmortizationOfOperatingLeaseRightOfUseAssets	851760	USD
CY2020	ino	Change In Value Of Common Stock Warrants ChangeInValueOfCommonStockWarrants	0	USD
CY2019	ino	Change In Value Of Common Stock Warrants ChangeInValueOfCommonStockWarrants	0	USD
CY2018	ino	Change In Value Of Common Stock Warrants ChangeInValueOfCommonStockWarrants	-360795	USD
CY2020	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	75670977	USD
CY2019	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	1763652	USD
CY2018	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	15647523	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	10901320	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	10654622	USD
CY2020	ino	Non Cash Interest Expense NonCashInterestExpense	4077686	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-5889	USD
CY2018	ino	Non Cash Interest Expense NonCashInterestExpense	0	USD
CY2020	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	0	USD
CY2019	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	1962	USD
CY2018	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	72561	USD
CY2020	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	USD
CY2019	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-5397	USD
CY2018	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	USD
CY2020	us-gaap	Gain Loss On Investments GainLossOnInvestments	-588270	USD
CY2019	us-gaap	Gain Loss On Investments GainLossOnInvestments	476368	USD
CY2018	us-gaap	Gain Loss On Investments GainLossOnInvestments	-1342005	USD
CY2020	ino	Settlement Of Receivable With Shares Of Common Stock From Equity Security SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity	1713770	USD
CY2019	ino	Settlement Of Receivable With Shares Of Common Stock From Equity Security SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity	0	USD
CY2018	ino	Settlement Of Receivable With Shares Of Common Stock From Equity Security SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity	0	USD
CY2020	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	4121075	USD
CY2019	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2018	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-26913	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-14529	USD
CY2020	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	36556658	USD
CY2019	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-3090557	USD
CY2018	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-1988567	USD
CY2020	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-4584610	USD
CY2019	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	USD
CY2018	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	USD
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain EquitySecuritiesFvNiUnrealizedGain	1695497	USD
CY2019	us-gaap	Equity Securities Fv Ni Unrealized Gain EquitySecuritiesFvNiUnrealizedGain	0	USD
CY2018	us-gaap	Equity Securities Fv Ni Unrealized Gain EquitySecuritiesFvNiUnrealizedGain	0	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	-266215	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-15902	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-471172	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17859894	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-844423	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2616288	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2686844	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	593461	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	251964	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	38849572	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	178008	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1194316	USD
CY2020	ino	Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	-374107	USD
CY2019	ino	Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	-70665	USD
CY2018	ino	Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	-725202	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	23285424	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2026	USD
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	30644	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3115828	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4337829	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	550407	USD
CY2020	ino	Increase Decrease In Accrued Clinical Trial Expense IncreaseDecreaseInAccruedClinicalTrialExpense	5962381	USD
CY2019	ino	Increase Decrease In Accrued Clinical Trial Expense IncreaseDecreaseInAccruedClinicalTrialExpense	-1622037	USD
CY2018	ino	Increase Decrease In Accrued Clinical Trial Expense IncreaseDecreaseInAccruedClinicalTrialExpense	-2940128	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	135650	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-248063	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	50849	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-68078	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-180450	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1016836	USD
CY2020	ino	Increase Decrease In Deferred Revenue From Related Parties IncreaseDecreaseInDeferredRevenueFromRelatedParties	5725	USD
CY2019	ino	Increase Decrease In Deferred Revenue From Related Parties IncreaseDecreaseInDeferredRevenueFromRelatedParties	-1800	USD
CY2018	ino	Increase Decrease In Deferred Revenue From Related Parties IncreaseDecreaseInDeferredRevenueFromRelatedParties	-140535	USD
CY2020	us-gaap	Straight Line Rent StraightLineRent	0	USD
CY2019	us-gaap	Straight Line Rent StraightLineRent	0	USD
CY2018	us-gaap	Straight Line Rent StraightLineRent	398357	USD
CY2020	ino	Increase Decrease In Operating Lease Right Of Use Asset Lease Liability Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet	-2091855	USD
CY2019	ino	Increase Decrease In Operating Lease Right Of Use Asset Lease Liability Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet	-1733599	USD
CY2020	ino	Increase Decreasein Deferred Grant Funding Current IncreaseDecreaseinDeferredGrantFundingCurrent	1409098	USD
CY2019	ino	Increase Decreasein Deferred Grant Funding Current IncreaseDecreaseinDeferredGrantFundingCurrent	1899364	USD
CY2018	ino	Increase Decreasein Deferred Grant Funding Current IncreaseDecreaseinDeferredGrantFundingCurrent	4165848	USD
CY2020	ino	Increase Decreasein Deferred Grant Funding From Affiliate Current IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent	-784925	USD
CY2019	ino	Increase Decreasein Deferred Grant Funding From Affiliate Current IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent	816342	USD
CY2018	ino	Increase Decreasein Deferred Grant Funding From Affiliate Current IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent	27083	USD
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	20720	USD
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-48507	USD
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	87333	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-177979046	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-97850136	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73550156	USD
CY2020	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	156216677	USD
CY2019	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	100950301	USD
CY2018	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	88155046	USD
CY2020	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	62991023	USD
CY2019	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	92893232	USD
CY2018	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	132659976	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1520665	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	987926	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2085022	USD
CY2020	ino	Proceeds From Sale Of Equity Securities Fvni ProceedsFromSaleOfEquitySecuritiesFVNI	40125418	USD
CY2019	ino	Proceeds From Sale Of Equity Securities Fvni ProceedsFromSaleOfEquitySecuritiesFVNI	0	USD
CY2018	ino	Proceeds From Sale Of Equity Securities Fvni ProceedsFromSaleOfEquitySecuritiesFVNI	0	USD
CY2020	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	2774851	USD
CY2019	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	0	USD
CY2018	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	0	USD
CY2020	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	1399999	USD
CY2019	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	0	USD
CY2018	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-58795751	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9044995	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	42419908	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	97443617	USD
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	3314757	USD
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	454486400	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9089010	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	29227776	USD
CY2020	ino	Proceedsfrom Stock Optionand Warrant Exercises ProceedsfromStockOptionandWarrantExercises	12269801	USD
CY2019	ino	Proceedsfrom Stock Optionand Warrant Exercises ProceedsfromStockOptionandWarrantExercises	112522	USD
CY2018	ino	Proceedsfrom Stock Optionand Warrant Exercises ProceedsfromStockOptionandWarrantExercises	2421136	USD
CY2020	ino	Proceeds From Payments For Stock Options Exercisedand Exercise Of Warrants Net Of Tax Withholdings ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings	-4028177	USD
CY2019	ino	Proceeds From Payments For Stock Options Exercisedand Exercise Of Warrants Net Of Tax Withholdings ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings	-892928	USD
CY2018	ino	Proceeds From Payments For Stock Options Exercisedand Exercise Of Warrants Net Of Tax Withholdings ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings	-611610	USD
CY2020	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	2379969	USD
CY2019	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	2960131	USD
CY2018	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	171620	USD
CY2019	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2018	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	465279613	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	105397595	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	31037302	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27205	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	228532021	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1497536	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-92946	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22196097	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23693633	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23786579	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	250728118	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22196097	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23693633	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	136711	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	559646	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	4624764	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	2717585	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2020	ino	Equity Component Of Convertible Debt Issued EquityComponentOfConvertibleDebtIssued	0	USD
CY2019	ino	Equity Component Of Convertible Debt Issued EquityComponentOfConvertibleDebtIssued	15752698	USD
CY2018	ino	Equity Component Of Convertible Debt Issued EquityComponentOfConvertibleDebtIssued	0	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	14634769	USD
CY2020	us-gaap	Nature Of Operations NatureOfOperations	The Company<div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio Pharmaceuticals, Inc. (the “Company” or “INOVIO”), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus (HPV). INOVIO's DNA medicines pipeline is comprised of three types of product candidates: DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMAbs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In clinical trials, INOVIO has demonstrated that DNA medicines can be delivered directly into cells in the body through its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted pathogens and cancers. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's novel DNA medicine candidates are made using its proprietary SynCon</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology that uses a computer algorithm designed to identify and optimize the DNA sequence of the target antigen (be it virus or a tumor). INOVIO then creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce antigens to help the person’s immune system recognize and destroy cancerous or virally infected cells.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's patented CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trial data to date has shown a favorable safety profile of INOVIO's DNA medicines delivered directly into cells in the body using the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart device in more than 7,000 administrations across more than 3,000 patients.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> INOVIO's corporate strategy is to advance, protect and, once approved, commercialize its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and clinically validate an array of DNA medicine candidates that target HPV-associated diseases, cancer, and infectious diseases, such as COVID-19 (SARS-CoV-2). The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's partners and collaborators include ApolloBio Corporation.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> AstraZeneca, Beijing Advaccine, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), The U.S. Department of Defense (DoD), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency’s Medical CBRN Defense Consortium (MCDC), International Vaccine Institute (IVI), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head & neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis (RRP); glioblastoma multiforme (GBM); prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div>
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-166400000	USD
CY2020Q4	ino	Working Capital WorkingCapital	429500000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-906200000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	411600000	USD
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div>
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3100000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3700000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	159700000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	137200000	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16190768	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	30737956	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10449150	shares
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	127000	USD
CY2019	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	293000	USD
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	744000	USD
CY2019	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	594000	USD
CY2020	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	1300000	USD
CY2019Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1584598	USD
CY2019	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	118000	USD
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	1700000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	12	investment
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0	investment
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	159239931	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2365899	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	690895	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	160914935	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	8819023	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-75670977	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	84490000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4111930	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30481897	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7411220	USD
CY2020Q4	ino	Prepaid Manufacturing Expenses Current PrepaidManufacturingExpensesCurrent	35661947	USD
CY2019Q4	ino	Prepaid Manufacturing Expenses Current PrepaidManufacturingExpensesCurrent	0	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	4695509	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	40357456	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1584598	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	27341715	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15993571	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11348144	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25939475	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13166458	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12773017	USD
CY2020	us-gaap	Depreciation Depreciation	3000000.0	USD
CY2019	us-gaap	Depreciation Depreciation	3600000	USD
CY2018	us-gaap	Depreciation Depreciation	3700000	USD
CY2020	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	227000	USD
CY2020	us-gaap	Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1	200000	USD
CY2019Q4	ino	Accrued Subcontract Expenses AccruedSubcontractExpenses	273508	USD
CY2020Q4	ino	Accrued Subcontract Expenses AccruedSubcontractExpenses	247796	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	7003239	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	2076772	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	21203808	USD
CY2020Q4	us-gaap	Goodwill Goodwill	10513371	USD
CY2020Q4	us-gaap	Goodwill Goodwill	10513371	USD
CY2019Q4	us-gaap	Goodwill Goodwill	10513371	USD
CY2019Q4	us-gaap	Goodwill Goodwill	10513371	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	10473761	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7326991	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3146770	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	10473761	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6779910	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3693851	USD
CY2020Q4	ino	Goodwill And Intangible Assets Gross GoodwillAndIntangibleAssetsGross	20987132	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7326991	USD
CY2020Q4	ino	Goodwill And Intangible Assets Net GoodwillAndIntangibleAssetsNet	13660141	USD
CY2019Q4	ino	Goodwill And Intangible Assets Gross GoodwillAndIntangibleAssetsGross	20987132	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6779910	USD
CY2019Q4	ino	Goodwill And Intangible Assets Net GoodwillAndIntangibleAssetsNet	14207222	USD
CY2020Q4	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	825516	USD
CY2019Q4	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	6919081	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	13127257	USD
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	8967897	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	18237258	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1351000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3147000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	547000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1100000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1200000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	521000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	493000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	276000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	253000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	253000	USD
CY2018	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2019	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2020	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2020	ino	Convertible Preferred Stock Shares Issued Upon Conversion Conversion Price Per Share ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare	27.20
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4400000	USD
CY2019Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3400000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M24D
CY2019	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y8M12D
CY2020Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	8906624	shares
CY2020	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2020Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	6.78
CY2020Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	6079497	shares
CY2020Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	6.58
CY2020	ino	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue	24200000	USD
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	16800000	USD
CY2020	ino	Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm	P5Y8M12D
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-19908000	USD
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	4.44
CY2020Q4	ino	Sharebased Compensation Arrangementby Sharebased Payment Award Options Expectedto Vest Outstanding Number SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber	8906624	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9265390	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.72
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2126182	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.17
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2178252	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.63
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	306696	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6.40
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8906624	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.78
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	78750	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	6.27
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	324502	shares
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	5.17
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	119091	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.87
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.19
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.86
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12300000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	113000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1500000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14200000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	25000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	910000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	3968000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4045000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4023000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3001000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3063000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	9888000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	27988000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7595000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	20393000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2329000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18064000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y4M24D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085
CY2020	us-gaap	Lease Cost LeaseCost	3400000	USD
CY2019	us-gaap	Lease Cost LeaseCost	3200000	USD
CY2018	us-gaap	Lease Cost LeaseCost	3400000	USD
CY2020Q4	ino	Lessee Number Of Lease Agreements Entered Into LesseeNumberOfLeaseAgreementsEnteredInto	2	lease
CY2020Q4	ino	Lessee Operating Lease Areaof Land Under Lease LesseeOperatingLeaseAreaofLandUnderLease	13500	sqft
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-162664355	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-120809112	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-94798019	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-225949	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-162890304	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-120809112	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-94798019	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	4000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2170000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	6000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2170000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-263000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-263000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-257000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2170000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-34207000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-25370000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	0	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	0	USD
CY2019	ino	Effective Income Tax Rate Reconciliation Nondeductible Loss On Extinguishment Of Debt EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt	0	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-4000	USD
CY2020	ino	Effective Income Tax Reconciliation Foreign Withholding Taxes Amount EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount	0	USD
CY2019	ino	Effective Income Tax Reconciliation Foreign Withholding Taxes Amount EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount	0	USD
CY2018	ino	Effective Income Tax Reconciliation Foreign Withholding Taxes Amount EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount	2170000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	21428000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	25457000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	20898000	USD
CY2020	ino	Effective Income Tax Rate Reconciliation Nondeductible Loss On Extinguishment Of Debt EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt	14450000	USD
CY2018	ino	Effective Income Tax Rate Reconciliation Nondeductible Loss On Extinguishment Of Debt EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt	0	USD
CY2020	ino	Income Tax Reconciliation Statute Limitations IncomeTaxReconciliationStatuteLimitations	-2650000	USD
CY2019	ino	Income Tax Reconciliation Statute Limitations IncomeTaxReconciliationStatuteLimitations	-3838000	USD
CY2018	ino	Income Tax Reconciliation Statute Limitations IncomeTaxReconciliationStatuteLimitations	-3170000	USD
CY2020	ino	Income Tax Reconciliation Fair Value Warrant IncomeTaxReconciliationFairValueWarrant	0	USD
CY2018	ino	Income Tax Reconciliation Fair Value Warrant IncomeTaxReconciliationFairValueWarrant	-76000	USD
CY2019	ino	Effective Income Tax Rate Reconciliation Deconsolidation Of Subsidiary EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary	0	USD
CY2019	ino	Income Tax Reconciliation Fair Value Warrant IncomeTaxReconciliationFairValueWarrant	0	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1953000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1114000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1094000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	1068000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	1537000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	1268000	USD
CY2020	ino	Effective Income Tax Rate Reconciliation Deconsolidation Of Subsidiary EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary	853000	USD
CY2018	ino	Effective Income Tax Rate Reconciliation Deconsolidation Of Subsidiary EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary	0	USD
CY2020	ino	Effective Income Tax Reconciliation Expired Net Operating Lossesand Credits EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits	468000	USD
CY2019	ino	Effective Income Tax Reconciliation Expired Net Operating Lossesand Credits EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits	616000	USD
CY2018	ino	Effective Income Tax Reconciliation Expired Net Operating Lossesand Credits EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits	2176000	USD
CY2020	ino	Effective Income Tax Reconciliation Limited Net Operating Lossesand Credits EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits	-368000	USD
CY2019	ino	Effective Income Tax Reconciliation Limited Net Operating Lossesand Credits EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits	-616000	USD
CY2018	ino	Effective Income Tax Reconciliation Limited Net Operating Lossesand Credits EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits	-2176000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	12000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-9000	USD
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	USD
CY2018	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	920000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	831000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-102000	USD
CY2020	ino	Comprehensive Income Loss Tax Expense Benefit ComprehensiveIncomeLossTaxExpenseBenefit	0	USD
CY2019	ino	Comprehensive Income Loss Tax Expense Benefit ComprehensiveIncomeLossTaxExpenseBenefit	-257000	USD
CY2018	ino	Comprehensive Income Loss Tax Expense Benefit ComprehensiveIncomeLossTaxExpenseBenefit	2170000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-257000	USD
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5250000	USD
CY2019Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6300000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	127835000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other Tax Carryforwards DeferredTaxAssetsOtherTaxCarryforwards	13242000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	110788000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other Tax Carryforwards DeferredTaxAssetsOtherTaxCarryforwards	11737000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1628000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1506000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3256000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3255000	USD
CY2020Q4	ino	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	757000	USD
CY2019Q4	ino	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	889000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	1852000	USD
CY2020Q4	ino	Deferred Tax Asset Interest Expense DeferredTaxAssetInterestExpense	564000	USD
CY2019Q4	ino	Deferred Tax Asset Interest Expense DeferredTaxAssetInterestExpense	1122000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	542000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	645000	USD
CY2020Q4	ino	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	4283000	USD
CY2019Q4	ino	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	4722000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6127000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2413000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	163484000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	145229000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	159705000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	137159000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3779000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8070000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	179000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	160000	USD
CY2020Q4	ino	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	2676000	USD
CY2019Q4	ino	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	2894000	USD
CY2020Q4	ino	Deferred Tax Liabilities Financing Arrangement Discount DeferredTaxLiabilitiesFinancingArrangementDiscount	469000	USD
CY2019Q4	ino	Deferred Tax Liabilities Financing Arrangement Discount DeferredTaxLiabilitiesFinancingArrangementDiscount	2862000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	0	USD
CY2020Q3	us-gaap	Interest Income Operating InterestIncomeOperating	896710	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	1381000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	487000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	805000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	32000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	32000	USD
CY2020Q4	ino	Tax Benefits Expired TaxBenefitsExpired	10200000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11204000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9632000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8313000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1043000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1575000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1319000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	27000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	3000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	ino	Unrecognized Tax Benefits Increase Decrease In Other UnrecognizedTaxBenefitsIncreaseDecreaseInOther	-64000	USD
CY2019	ino	Unrecognized Tax Benefits Increase Decrease In Other UnrecognizedTaxBenefitsIncreaseDecreaseInOther	0	USD
CY2018	ino	Unrecognized Tax Benefits Increase Decrease In Other UnrecognizedTaxBenefitsIncreaseDecreaseInOther	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12210000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11204000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9632000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	10900000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	9900000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	8300000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1100000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1200000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1200000	USD
CY2020	ino	Collaborative Agreement Awarded Option Amount CollaborativeAgreementAwardedOptionAmount	6000000.0	USD
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5580581	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	236178	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	267187	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1327274	USD
CY2020Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26302561	USD
CY2020Q2	us-gaap	Interest Income Operating InterestIncomeOperating	1067399	USD
CY2020Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-5050092	USD
CY2020Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9350	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26455112	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22376575	USD
CY2020Q4	us-gaap	Operating Expenses OperatingExpenses	34920019	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19111188	USD
CY2020Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8617458	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10110506	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11071510	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7448354	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	36565618	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	33448085	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	26559542	USD
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-29339438	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-36329440	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-33180898	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-25232268	USD
CY2020Q4	us-gaap	Interest Income Operating InterestIncomeOperating	931168	USD
CY2020Q1	us-gaap	Interest Income Operating InterestIncomeOperating	416569	USD
CY2020Q4	us-gaap	Interest Expense InterestExpense	1068008	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	1984046	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	2846641	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	2803755	USD
CY2020Q4	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	0	USD
CY2020Q3	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	35306000	USD
CY2020Q2	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-97755000	USD
CY2020Q1	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-13221977	USD
CY2020Q4	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	306317	USD
CY2020Q3	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	26951898	USD
CY2020Q2	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-3883176	USD
CY2020Q1	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	13181619	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	1070975	USD
CY2020Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	1315980	USD
CY2020Q2	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	4358634	USD
CY2020Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22415201	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-136644	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-152102	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-425500	USD
CY2020Q4	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2020Q3	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2020Q2	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	4121075	USD
CY2020Q1	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	20931010	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-128270709	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33135404	USD
CY2020Q4	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1923179	USD
CY2020Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1759674	USD
CY2020Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-901757	USD
CY2020Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2020Q4	us-gaap	Profit Loss ProfitLoss	-24338380	USD
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-30421053	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-23951787	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	19171336	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	-129172466	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-33135404	USD
CY2020Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2020Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2020Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-469407	USD
CY2020Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-594350	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-24338380	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	19171336	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-128703059	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-32541054	USD
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.11
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.83
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	279488	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	31364917	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	866863	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	135673	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2829905	USD
CY2019Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22003955	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19137209	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22486266	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24389888	USD
CY2019Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8696586	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5681441	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5850101	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6975029	USD
CY2019Q4	us-gaap	Operating Expenses OperatingExpenses	30700541	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	24818650	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	28336367	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-28200694	USD
CY2019Q2	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-173212	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-28535012	USD
CY2019Q4	us-gaap	Interest Income Operating InterestIncomeOperating	587679	USD
CY2019Q3	us-gaap	Interest Income Operating InterestIncomeOperating	637438	USD
CY2019Q2	us-gaap	Interest Income Operating InterestIncomeOperating	755330	USD
CY2019Q1	us-gaap	Interest Income Operating InterestIncomeOperating	625535	USD
CY2019Q4	us-gaap	Interest Expense InterestExpense	2668837	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	2428671	USD
CY2019Q2	us-gaap	Interest Expense InterestExpense	2194783	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	656248	USD
CY2019Q4	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-4315105	USD
CY2019Q3	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	2551453	USD
CY2019Q2	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	0	USD
CY2019Q1	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	0	USD
CY2019Q4	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-1681401	USD
CY2019Q3	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-485841	USD
CY2019Q1	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-750103	USD
CY2019Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	263571	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	140956	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	127512	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-35839	USD
CY2019Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-38235146	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23536452	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29685847	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29351667	USD
CY2019Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-87764	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-106771	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-62800	USD
CY2019Q4	us-gaap	Profit Loss ProfitLoss	-38147382	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	-23536452	USD
CY2019Q2	us-gaap	Profit Loss ProfitLoss	-29579076	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-29288867	USD
CY2019Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-485344	USD
CY2019Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-445759	USD
CY2019Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-191850	USD
CY2019Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-69605	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-37662038	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-23090693	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-29387226	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-29219262	USD
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30

Files In Submission

Name	View Source	Status
0001055726-21-000018-index-headers.html	Edgar Link	pending
0001055726-21-000018-index.html	Edgar Link	pending
0001055726-21-000018.txt	Edgar Link	pending
0001055726-21-000018-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ino-12312020x10kex1014.htm	Edgar Link	pending
ino-12312020x10kex211.htm	Edgar Link	pending
ino-12312020x10kex231.htm	Edgar Link	pending
ino-12312020x10kex311.htm	Edgar Link	pending
ino-12312020x10kex312.htm	Edgar Link	pending
ino-12312020x10kex321.htm	Edgar Link	pending
ino-20201231.htm	Edgar Link	pending
ino-20201231.xsd	Edgar Link	pending
ino-20201231_cal.xml	Edgar Link	unprocessable
ino-20201231_def.xml	Edgar Link	unprocessable
ino-20201231_g1.jpg	Edgar Link	pending
ino-20201231_g2.jpg	Edgar Link	pending
ino-20201231_g3.jpg	Edgar Link	pending
ino-20201231_g4.jpg	Edgar Link	pending
ino-20201231_g5.jpg	Edgar Link	pending
ino-20201231_g6.jpg	Edgar Link	pending
ino-20201231_g7.jpg	Edgar Link	pending
ino-20201231_htm.xml	Edgar Link	completed
ino-20201231_lab.xml	Edgar Link	unprocessable
ino-20201231_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INO
INOVIO PHARMACEUTICALS, INC. Stock $ino

2020 Q4 Form 10-K Financial Statement

#000105572621000018 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INO INOVIO PHARMACEUTICALS, INC. Stock $ino

2020 Q4 Form 10-K Financial Statement

#000105572621000018 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INO
INOVIO PHARMACEUTICALS, INC. Stock $ino